Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,174 across all filing types
Latest filing 2024-12-13 Capital/Financing Update
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the acquisition of anti-diabetes trademarks by Lupin Limited from Boehringer Ingelheim. It is addressed to stock exchanges and references compliance with SEBI Listing Regulations. The content focuses on the acquisition details, strategic intent, and company background. There are no financial statements, detailed financial performance data, or regulatory filings such as annual or quarterly reports. The document is not a report itself but an announcement of a corporate transaction related to intellectual property acquisition. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including acquisitions that affect the company's portfolio and assets.
2024-12-13 English
Intimation regarding issuance of duplicate share certificate in lieu of lost share certificate.
Regulatory Filings Classification · 95% confidence The document is a compliance certificate issued under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. It details the issuance of duplicate share certificates in lieu of lost certificates. The document is short (2674 characters) and is a formal compliance communication rather than a financial report or announcement of financial results. It does not contain financial statements, management discussion, or any report-type content. It is not an announcement of voting results, board changes, or capital changes. The document fits the category of a regulatory filing related to compliance with stock exchange regulations.
2024-12-13 English
Issue of Duplicate Share Certificate
Regulatory Filings Classification · 95% confidence The document is a compliance certificate issued under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. It details the issuance of duplicate share certificates in lieu of lost certificates. The document is short (2674 characters) and is a formal attestation or certification by the company secretary, not a financial report or announcement of financial results. It does not contain financial data or management discussion, nor is it an announcement of voting results or capital changes. It is a regulatory compliance filing related to share certificate management. Therefore, it fits best under Regulatory Filings (RNS) as a compliance certificate under SEBI regulations.
2024-12-13 English
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurence Corporation of India
Regulatory Filings
2024-12-09 English
News Verification
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (NSE and BSE) providing clarification and confirmation regarding a news item about Lupin Limited receiving tentative approval from the US FDA for a drug. It references compliance with SEBI Listing Regulations and states that the event was not material and hence not disclosed earlier. The document is short (2657 characters) and serves as a regulatory clarification or confirmation rather than a financial report or announcement of financial results. It does not contain financial statements, earnings data, or detailed management discussion. It is not an announcement of voting results, capital changes, or management changes. It is a regulatory communication responding to surveillance queries and clarifying information to the exchanges. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2024-12-02 English
Clarification / confirmation on the news item appearing in www.business-standard.com
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (NSE and BSE) providing clarification and confirmation regarding a news item about Lupin Limited receiving tentative approval from the US FDA for a drug. It references compliance with SEBI Listing Regulations and states that the event was not material and hence not disclosed earlier. The document is short (2657 characters) and serves as a regulatory disclosure or clarification rather than a financial report or announcement of financial results. It does not contain financial statements, management discussion, or detailed financial data. It is not an earnings release, annual report, or any detailed report but a regulatory communication to clarify market rumors and confirm compliance. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance disclosures that do not fit other categories.
2024-11-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.